Role of innate and adaptive immunity in the efficacy of anti-HER2 monoclonal antibodies for HER2-positive breast cancer
Antonino Musolino(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Maria Michiara, Angelica Sikokis(University of Parma), Daniela Boggiani(University of Parma), Daniele Zanoni(Istituti Ospitalieri di Cremona), Giuseppe Maglietta(University of Parma), Antonio Frassoldati(Italian Oncology Group of Clinical Research), Enrico Maria Silini(Ospedale di Parma), Gabriele Missale(University of Parma), Benedetta Pellegrino(University of Parma)
Cited by 21
Related Papers
Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response.
|Journal of Clinical Investigation|1996|661
Sentinel European Node Trial (SENT): 3-year results of sentinel node biopsy in oral cancer
|European Journal of Cancer|2015|386
Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study
|Journal of Clinical Oncology|2012|368
Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results
|Annals of Oncology|2012|339
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
|EMBO Molecular Medicine|2018|271